Article · 31 Dec 2025
Conference abstract
Osteoprotegrin (OPG) - receptor activator of NF-KB (RANK) - RANK ligand (RANKL) signaling system components and pro-inflammatory cytokins in blood serum of patients with primary bone neoplasms
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
OPG/RANK/RANKL ligand-receptor system directly regulates osteoclast differentiation and osteolysisis. It modulates cancer cell migration controlling bone metastases development. Less is known about its role in primary bone neoplasms, though anti- RANKL antibodies have been already successfully used as targeted therapy of some bone tumors. The aim of this study was to measure OPG/RANK/RANKL and some pro-inflammatory moleculesâ?? in blood serum of primary bone tumor patients for assessment of their associations with key tumor characteristics and possible diagnostic, prognostic or predictive value. 163 primary bone tumor patients (37 osteosarcoma, 41 chondrosarcoma, 12 chordoma, 7 Ewing sarcoma, 2 pleomorhic undifferentiated sarcoma, 2 fibrosarcoma; 30 benign and 32 borderline giant cell bone tumor - GCBT) were involved. Control group comprised 71 persons. OPG, sRANKL, sRANK, IL-6, 8, 16, and Receptor for Advanced Glycation End product (sRAGE) serum levels were measured by standard ELISA kits. The highest sRANKL, OPG and IL-6 levels were revealed in GCBT patients, while serum sRANK, IL-8 and IL-16 did not differ between groups. IL-6 was also significantly increased in patients with benign and malignant tumors as compared to control, and sRAGE was decreased in malignant and borderline bone tumor patients as compared to those with benign tumors and control. Thus, RANK/RANKL/OPG and IL-6 serum levels in GCBT characterized by active bone destruction are markedly increased as compared not only to control and benign bone tumor patients, but also to those with bone sarcomas. Hence, these proteins can be regarded as promising serologic markers and therapeutic targets in this rare disease.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmacogenomics & Pharmacoproteomics.
Article · 31 Dec 2025
Genetic Determinants of Individual Drug Response
Article · 31 Dec 2025
Genetic Variation in Drug Metabolism, Transport, and Treatment Response
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacogenomics & Pharmacoproteomics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Nikolay Kushlinskii”
- BylineArticles whose byline prints “E S Gershtein”
- BylineArticles whose byline prints “Yu S Timofeev”
- BylineArticles whose byline prints “I V Babkina”
- BylineArticles whose byline prints “E A Korotkova”
- BylineArticles whose byline prints “O I Kostyleva”
- BylineArticles whose byline prints “A A Zuev”
- BylineArticles whose byline prints “I V Boulitcheva”
